Company Filing History:
4 out of 140 
4 out of 950 
4 out of 61 Years Active: 2008-2012
Title: Hideo Takasu: Innovator in Cancer Vaccine Development
Introduction
Hideo Takasu is a prominent inventor based in Nishinomiya, Japan, known for his significant contributions to the field of cancer immunotherapy. With a total of four patents to his name, Takasu has focused on developing innovative solutions to combat cancer through peptide-based vaccines.
Latest Patents
Among his latest patents, Takasu has developed a novel tumor antigen peptide that serves as a cancer vaccine. This invention features a peptide dimer, where two peptide monomers, consisting of 7-30 amino acids and including at least one cysteine residue, are linked by a disulfide bond. Additionally, he has worked on HLA-A24-restricted cancer antigen peptides derived from WT1, which are designed to induce cytotoxic T lymphocytes (CTLs) in vivo. These peptides and their corresponding polynucleotides can be utilized in cancer vaccines, offering potential treatment options for numerous cancer patients.
Career Highlights
Throughout his career, Hideo Takasu has been associated with notable companies such as Dainippon Sumitomo Pharma Co., Ltd. and Chugai Seiyaku Kabushiki Kaisha. His work in these organizations has contributed to advancements in pharmaceutical research and development, particularly in the area of cancer therapies.
Collaborations
Takasu has collaborated with esteemed colleagues, including Haruo Sugiyama and Masashi Gotoh, to further enhance the impact of his research and innovations in the field of cancer treatment.
Conclusion
Hideo Takasu's work in developing peptide-based cancer vaccines showcases his dedication to advancing medical science and improving patient outcomes. His innovative patents and collaborations highlight his significant role in the fight against cancer.